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Summary
Background and aim: Prisons in Egypt do not currently screen for blood-borne viruses,
and there are no statistics concerning the prevalence of hepatitis C virus, hepatitis B
virus or human immunodeﬁciency virus among prisoners. This study was performed
to detect the prevalence of antibodies against hepatitis C, hepatitis B core and
human immunodeﬁciency virus among Egyptian prisoners.
Methods: The study was conducted in an Egyptian prison. The prisoners voluntarily
completed a risk factor questionnaire and provided blood specimens for testing
for antibodies against hepatitis C virus, hepatitis B virus core antigen and human
immunodeﬁciency virus. Positive results were conﬁrmed by the detecting HCV RNA
via polymerase chain reaction. Multivariate regression analysis was performed to
determine the factors that were independently associated with positive HCV sero-
logy.
Results: Five hundred resident prisoners were screened. The prevalence of hepatitis
C virus antibodies was 15.8% (79/500), and viremia was conﬁrmed by PCR in 77.2%
(61/79) of the antibody-positive prisoners. The prevalence of antibodies to hepatitis
B core antigen was 9.8% (49/500), and 1.2% (6/500) of prisoners were dually infected
with HBV and HCV. Antibodies to human immunodeﬁciency virus were not detected
in any of the prisoners. The best predictor for hepatitis C and hepatitis B infection
was a history of intravenous drug use (P < 0.011 for HBV and P < 0.001 for HCV), a
period of >10 years spent in prison (P < 0.052 for HBV and P < 0.021 for HCV) and
shared toiletries (P < 0.059 for HBV and P < 0.002 for HCV).
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Conclusion: Hepatitis C and hepatitis B virus infections constitute an important public
health problem in prisons. Public health strategies to prevent morbidity and mortality
from these infections should include hepatitis B vaccination, HCV testing, counseling
and medical management of infected prisoners.
dulaziz University for Health Sciences. Published by Elsevier
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were approached individually. A researcher assisted
those with literacy difﬁculties.© 2013 King Saud Bin Ab
Ltd. All rights reserved.
ntroduction
he prevention of blood-borne pathogen transmis-
ion is a high priority for the Ministry of Health and
opulation (MOHP) in Egypt [1]. Despite the avail-
bility of several reports concerning anti-hepatitis
virus (HCV) seropositivity among apparently
ealthy Egyptian populations, little attention has
een paid to the HCV and hepatitis B virus (HBV)
urden of Egyptian prisoners.
HCV infection is highly endemic in Egypt; there is
vidence of chronic HCV infection in 10—15% of the
opulation [2]. Numerous studies have identiﬁed
iverse risk factors associated with HCV transmis-
ion [3].
Similar to HCV, there are few studies evaluating
he risks associated with HBV transmission in Egypt.
he epidemiology of HBV infections in Egypt has
ot been well characterized. Cross-sectional stud-
es indicate that HBV is of intermediate endemicity,
ith 3—5% of the population chronically infected
4].
The reported high prevalences of hepatitis C
irus (HCV), hepatitis B virus (HBV) and human
mmunodeﬁciency virus (HIV) in prison populations
s attributed to the disproportionate number of
risoners who engage in risky behavior, particularly
ntravenous drug users (IDUs). There are concerns
hat prisons could serve as reservoirs to amplify
isease transmission to the wider community upon
he release of inmates who became infected while
ncarcerated. Such reservoirs could be formed by
he high prevalence of infections such as HIV, HBV
nd HCV among inmates, particularly those with a
istory of intravenous drug use [5].
The effects of intra-prison disease transmission
re not limited to those that are incarcerated,
s the risk for continued transmission extends to
he general community to which the ex-offender
eturns. Thus, interventions addressing the pre-
ention of infections in prisons affect the larger
ommunity [6].
Health care in Egyptian prisons is provided in an
utpatient clinic by one general practitioner. Within
day of arrival, prisoners are medically examined,
nd those who are ill are directly admitted into
D
Che prison clinic. The living conditions are adequate
ith respect to sanitary facilities, water, light, ven-
ilation, sleeping accommodations and food. There
s no published data regarding the burden of HBV,
CV and HIV infection among prisoners in Egypt.
o date, HCV, HBV and HIV testing has been imple-
ented inside the prison only upon request. The
ractice of risky behavior, such as tattooing and
haring toiletries, occurs frequently during incar-
eration.
We conducted this study to determine the preva-
ence and behavioral correlates of HCV, HBV and HIV
nfections among Egyptian prisoners.
The identiﬁcation of risk factors in this study
nd others can form the basis for developing a
omprehensive strategy to prevent the transmission
f blood-borne pathogens in prisons. The strategy
hould include a program that targets HBV pre-
ention efforts, including vaccination for high-risk
roups, raising public awareness and demands for
afety and infection control standards in prisons.
atients and methods
his study was conducted in one of the Egyptian
risons in the Minia governorate. Five hundred (109
emales and 391 males) of the 1200 eligible inmates
n the prison were studied. The inmates that par-
icipated in the study had been incarcerated for at
east 24 months, and they were selected by random
ampling. After obtaining written informed consent
rom each subject, a questionnaire was completed
o gather information regarding sociodemograph-
cs, prison history and risk factors for HCV infection.
esearchers met groups of 5 to 10 prisoners. The
urvey was explained, and prisoners were advised
hat the survey was voluntary and conﬁdential. No
ncentives were offered. The prisoners who did not
ant to meet the researchers in a group settingThe study was approved by the Prison Service
irectorate of Health Care and the Research Ethics
ommittee of Mina University, Egypt.
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Serological assay
Serum samples were tested for anti-HCV antibodies
according to the manufacturer’s instructions with
a third-generation enzyme immunoassay (Cortez
Diagnostics, California, USA).
Sera were tested for antibodies against the hep-
atitis B core (anti-HBc Ab) using the commercially
available Diagnostics anti-HBc EIA enzyme-linked
immunosorbent assay (DIASORIN, Italy). HIV sero-
logy was performed using Standard Diagnostic, Inc.
(Kyonggi-do, Korea) and ﬂuorescence assay (bio
Mérieux S.A., France and bio Mérieux Vitek, Inc.,
USA).
Detection of hepatitis C by real-time PCR
Sera that tested positive for anti-HCV antibod-
ies were further tested for HCV RNA. The RNA
extraction was automated by a Qiacube instrument
(Qiagen, Germany), and ampliﬁcation was then
performed by real-time PCR. PCR products were
obtained using 25L reactions (16.5L master mix
and 8.5L RNA). The ampliﬁcation conditions were
performed as follows: 95 ◦C for 10min, followed by
40 cycles for 15 s at 95 ◦C, 60 s at 60 ◦C and 90 s
at 72 ◦C and ending with a single 10min extension
step at 72 ◦C (Applied Biosystems, USA). The value
for undetectable HCV RNA was 50 IU/mL.
Clinical history and examination
The clinical history and examination was performed
by a clinician and a well-trained ultrasonographer.
Thorough clinical histories were taken and exami-
nations were given for seropositive prisoners. For
this, special emphasis was given to symptoms sug-
gestive of chronic liver disease, such as fatigue,
dyspepsia, fever, itching, change in the color of
sclera and urine, abdominal pain, abdominal dis-
tension, swelling of lower limbs, hematemesis,
melena, bleeding tendencies and a disturbed level
of consciousness.
The general examination gave special emphasis
to signs of chronic liver diseases, such as a disturbed
level of consciousness, jaundice, scratch marks,
pallor, gynecomastia, ﬂapping tremors, palmer ery-
thema, spider nevi, ﬁnger clubbing and edema of
the lower limbs.
The abdominal examination emphasized abdom-
inal contour, divarication of recti, subcostal angle,
hair distribution and dilated veins. The liver was
palpated to assess its size, surface, consistency,
edge and tenderness. Percussion for ascites was
performed.
T
T
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The abdominal ultrasonography examination was
erformed to detect liver size, surface, echo pat-
ern, hepatic focal lesions and portal vein diameter.
plenic size, splenic vein diameter and the pres-
nce of ascites were also reported.
Cirrhosis was diagnosed based on clinical,
iochemical and imaging criteria. In this study,
decreased ALT/AST ratio, prolonged PT and
hrombocytopenia were used to diagnose cirrhosis;
his discriminated score was reported by Bonacini
t al. [7].
For patients with normal- or small-sized fatty
iver, cirrhosis was diagnosed by ultrasound with
ne of the following: coarse, bright hepatic
arenchyma or a caudate-to-right lobe ratio of
0.6 [8].
aboratory tests
aboratory testing included serum ALT levels (up
o 40U/L), total bilirubin (0.1—1.0mg/L), albu-
in (3.5—5.2 g/L), prothrombin time (11—12 s) and
latelet counts (150—400× 109 L−1).
tatistical analysis
he results were expressed as numbers (%). The
omparison between the categorical data [n (%)]
as performed using the Chi square test. The SPSS
omputer program (version 11 for Windows) was
sed for data analysis. Multivariate regression anal-
sis was used to identify the factors associated with
ositive test results. A P value equal to or less than
.05 was considered signiﬁcant.
esults
ubject characteristics
uring an 18-month period, a total of 500 prison-
rs gave written informed consent to participate in
he study. The mean age of the prisoners included
n the study was 41.0± 10.2 years (range: 28—62).
reater than 86% were married, 3.9% were single
nd 9.7% were divorced or widowed. Fourteen per-
ent of the resident prisoners had been imprisoned
reviously, and their average time spent in prison
as 12.4 (3.0—22) years. Greater than 40.2% of the
risoners performed manual labor, and only 1.4%
orked in health care services (Table 1).he prevalence of viral antibodies
he prevalence rate of antibodies against
epatitis C virus was 15.8% (79/500). Among
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Table 1 Socio-demographic characteristics of the prisoners, by hepatitis B virus, and hepatitis C virus.
Anti-HBc HCV-Ab conﬁrmed by PCRd Combined HBV +HCV infection
Positive
49 (9.8%)
Negative
451 (90.2%)
Positive
61 (12.2%)
Negative
439 (87.8%)
Positive
6 (1.2)
Negative
494 (98.8%)
Age
≤30 9 (18.4) 84 (18.6) 6 (9.8) 87 (19.8) 0 (0) 93 (18.8)
30—45 13 (26.5) 257 (57) 15 (24.6) 255 (58.1) 3 (50) 267 (54.0)
>45 27 (55.1) 110 (24.4) 40 (65.6) 97 (22.1) 3 (50) 134 (27.2)
aP value <0.041 <0.012 <0.401
Sex
Female 8 (16.3) 101 (22.4) 11 (18.0) 98 (22.3) 1 (16.7) 108 (21.9)
Male 41 (83.7) 350 (77.6) 50 (82.0) 341 (77.7) 5 (83.3) 386 (78.1)
bP value <0.003 <0.001 <0.001
Residence
Urban 21 (42.9) 328 (72.7) 35 (57.4) 314 (71.5) 2 (33.3) 347 (70.2)
Rural 28 (57.1) 123 (27.3) 26 (42.6) 125 (28.5) 4 (66.7) 147 (29.8)
P value <0.091 <0.615 <0.523
Education
No formal education 11 (22.4) 194 (43.0) 11 (18.0) 194 (44.2) 2 (33.3) 203 (41.1)
Basic education 10 (20.4) 45 (10.0) 14 (23.0) 41 (9.3) 3 (50) 52 (10.5)
Secondary education 17 (34.7) 147 (32.6) 17 (27.9) 147 (33.5) 0 (0) 164 (33.2)
Higher education 11 (22.4) 65 (14.4) 19 (31.1) 57 (13) 1 (16.7) 75 (15.2)
P value <0.101 <0.291 <0.071
Occupation
Jobless 13 (26.5) 156 (34.6) 17 (27.9) 151 (34.4) 2 (33.3) 166 (33.6)
Farmers 10 (20.4) 44 (9.8) 10 (16.4) 43 (9.8) 0 (0) 53 (10.7)
Manual 11 (22.4.) 190 (42.1) 18 (29.4) 183 (41.7) 3 (50) 198 (40.1)
Professional 12 (24.5) 57 (12.6) 12 (19.7) 59 (13.4) 1 (16.7) 70 (14.2)
Medical and
paramedical jobs
3 (6.2) 6 (12.2) 4 (6.6) 3 (0.7) 0 (0) 7 (1.4)
P value <0.102 <0.912 <0.721
Duration spent in the prison
<5 years 8 (16.3) 177 (39.2) 5 (8.2) 80 (41.0) 0 (0) 185 (37.4)
5—10 years 13 (26.5) 142 (31.5) 20 (32.8) 135 (30.8) 2 (33.3) 153 (31.0)
>10 years 28 (57.2) 132 (29.3) 36 (59.0) 124 (28.2) 4 (66.7) 156 (31.6)
cP value <0.053 <0.002 <0.055
Anti-HBc: hepatitis B anticore; HCV: hepatitis C virus; PCR: polymerase chain reaction. Data are shown as n and %.
a Comparing between different groups of ages.
b Comparing between males and females.
c n.
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d HCV RNA among those who were anti-HCV seropositive (to
nti-HCV-positive subjects, 61 (12.2%) had viremia
y PCR. The prevalence of antibodies against the
epatitis B core antigen was 9.8% (49/500), and
o-infections with HCV and HBV were reported
n 1.2% of subjects. HIV antibodies were not
etected in any of the prisoners. The antibody
revalence rates by selected sociodemographic
ata are shown in Table 1. The highest prevalences
o
h
f
Aumber tested was 79).
f HCV-Ab and HBc-Ab were recorded among
he age group of greater than 45 years, and the
owest prevalences were identiﬁed among the
ge group of less than 30 years. The prevalences
f HBc-Ab, HCV-Ab and dual infections were
igher in males (83.7%, 82.0%, and 83.3%) than in
emales. The highest prevalences of HBc-Ab, HCV-
b and dual infections were reported in resident
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Table 2 Multivariate regression analysis of factors associated with HBV and HCV infection.
Variable Odds Ratio (95% CI) P value
Crude Adjusteda
Antibodies to hepatitis B core antigen (N=49)
Urban residence (N = 349) 2.9 (1.6—3.1) 1.6 (0.8—1.9) 0.811
Age >45 years (N = 137) 2.3 (1.6—3.7) 1.6 (0.9—2.5) 0.147
Job (paramedical jobs) (N = 7) 2.2 (1.1—3.1) 1.9 (0.5—2.1) 0.096
Male sex (N = 391) 3.1 (2.9—4.3) 2.1 (1.55—2.8) 0.072
Education (higher education) (N = 76) 3.6 (1.7—5.8) 1.1 (0.8—1.5) 0.496
History of injecting drug use (N = 42) 5.6 (6.1—7.5) 3.9 (3.5—4.9) 0.011*
Previous imprisonment (N = 88) 4.9 (2.9—5.8) 1.7 (0.9—2.4) 0.159
Period spent in prison >10 years (N = 160) 7.1 (5.3—9.2) 2.5 (1.8—3.1) 0.052*
Dental procedure (N = 68) 2.8 (1.1—3.5) 0.4 (0.15—1.4) 0.828
Shared toiletries (brushes and razors) (N = 139) 4.8 (2.7—6.9) 2.6 (1.4—2.9) 0.059*
Habitual alcohol consumption (N = 31) 1.5 (0.9—2.1) 0.5 (0.3—1.1) 0.391
Tattooing (N = 98) 1.9 (1.9—2.8) 0.2 (0.1—1.5) 0.506
High BMI > 25 (N = 59) 2.7 (1.9—3.3) 1.9 (1.4—2.2) 0.814
Diabetes mellitus (N = 14) 4.3 (2.1—6.9) 2.9 (0.9—4.1) 0.015*
Antibodies to hepatitis C virus conﬁrmed by qualitative PCRb (N =61)
Urban residence (N = 349) 1.5 (1.1—3.5) 0.9 (0.54—1.85) 0.401
Age >45 years (N = 137) 3.7 (1.9—6.9) 1.5 (0.6—3.2) 0.051*
Job (paramedical jobs) (N = 7) 0.8 (1.9—3.7) 0.5 (0.1—2.4) 0.112
Male sex (N = 391) 1.9 (1.5—4.3) 0.9 (0.1—2.7) 0.670
Education (higher education) (N = 76) 2.9 (1.8—3.9) 1.5 (0.78—2.8) 0.931
History of injecting drug use (N = 42) 6.3 (5.1—7.7) 4.1 (2.78—5.3) 0.001*
Previous imprisonment (N = 88) 4.1 (3.6—6.8) 2.4 (1.3—3.5) 0.053*
Period spent in prison >10 years (N = 160) 5.9 (4.1—6.7) 3.4 (1.2—4.8) 0.021b
Dental procedure (N = 68) 7.1 (4.1—8.9) 4.7 (2.7—6.3) 0.001*
Shared toiletries (brushes and razors) (N = 139) 5.8 (3.7—7.3) 3.9 (2.5—5.2) 0.002*
Habitual alcohol consumption (N = 31) 0.9 (0.6—2.6) 0.6 (0.2—1.1) 0.071
Tattooing (N = 98) 4.1 (3.9—7.4) 2.8 (2.2—4.7) 0.019*
High BMI > 25 (N = 59) 4.9 (2.4—6.9) 3.8 (0.9—4.5) 0.043*
Diabetes mellitus (N = 14) 6.1 (5.2—7.1) 3.9 (3.2—5.9) 0.013*
Anti-HBc: hepatitis B anticore; HCV: hepatitis C virus; PCR: polymerase chain reaction; CI: conﬁdence interval; BMI: body mass
index.
a Adjusted for age, sex, and demographic status in multiple logistic regression models.
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* Statistically signiﬁcant, Odds ratio: =1: no risk factor, <1:
prisoners who had spent more than 10 years in
prison.
Multivariate regression analysis
Logistic regression models were constructed to
clarify the associations between risky behavior and
HBV and HCV infections (Table 2). The most impor-
tant predictors of hepatitis B core antigen and
hepatitis C virus seropositivity were a history of
intravenous drug use, an incarceration period of
greater than 10 years, shared toiletries and dia-
betes mellitus (DM). Those who reported previous
imprisonment, dental procedures, age greater than
45 years, tattooing and high BMI were more likely
to be positive for antibodies to hepatitis C. There
was no signiﬁcant association between HCV or HBV
i
(
tumber tested was 79).
ctive factor, > 1: risk factor.
nfections with residence, age, job, gender, level of
ducation or alcohol consumption.
Most of the seropositive prisoners had evidence
f chronic liver disease. The HCV-positive prison-
rs had signiﬁcantly higher BMI, DM prevalence,
LT levels and thrombocytopenia compared to
BV-positive prisoners. However, there were no
igniﬁcant differences with respect to bilirubin
r albumin levels and prothrombin time. Cirrho-
is was detected in 8.2% of the prisoners positive
or only anti-HBc antibodies. In comparison, cir-
hosis was present in 18% of the prisoners with
nti-HCV antibodies. HCV infection was more signif-
cantly associated with cirrhosis than HBV infection
Table 3).
HCV RNA was detected by RT-PCR in 61 (77.2%) of
he prisoners who were anti-HCV positive. Of these,
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Table 3 Comparison of the clinical and laboratory data between HCV and HBV infected prisoners.
Clinical proﬁle Anti-HBc positive,
N = 49
HCV-Ab positive conﬁrmed
by PCR, N = 61
aAdjusted OR (95% CI) P value
N % N %
BMI (kg/m2)
≥25 16 (32.7) 43 (70.5) 3.6 (1.2—4.7) 0.001*
≤25 33 (67.3) 18 (29.5) 1.0
Diabetes mellitus 2 (4.1) 12 (19.7) 2.1 (1.7—2.7) 0.002*
Cirrhosis 4 (8.2) 11 (18.0) 1.6 (0.9—2.2) 0.011*
ALT level (U/L)
>40 12 (24.5) 20 (32.8) 1.2 (0.5—1.6) 0.052*
<40 37 (75.5) 41 (67.2) 1.0
Albumin (g/L)
≥3.5 42 (85.7) 51 (83.6) 1.0 0.904
<3. 7 (14.3) 10 (16.4) 0.4 (0.2—0.9)
Bilirubin (1mg/dL)
>3 g/dL 6 (12.2) 10 (16.4) 0.9 (0.5—1.7) 0.551
<3 g/dL 43 (87.8) 51 (83.6) 1.0
Platelets
>150.000mm−3 45 (91.8) 50 (82.0) 1.0 0.012*
<150.000mm−3 4 (8.2) 11 (18.0) 1.9 (1.1—2.8).
Prothrombin time
Normal 43 (87.8) 52 (85.2) 1.0 0.814
Prolonged 6 (12.2) 9 (14.6) 0.6 (0.2—0.9)
ALT, alanine aminotransferase; HCV: hepatitis C virus. HBc: hepatitis B core; PCR: polymerase chain reaction; BMI: body mass
index.
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* Statistically signiﬁcant.
7.4% had low viremia, 32.8% intermediate viremia
nd 9.8% high viremia.
iscussion
espite the availability of several reports con-
erning anti-HCV seropositivity among apparently
ealthy Egyptian populations, such as workers trav-
ling abroad [9], blood donors [10], military recruits
11], rural primary school children and inhabitants
f a rural village [12], little attention has been
aid to the burden of HCV and HBV infections
mong Egyptian prisoners. Therefore, this work is
he ﬁrst study to shed light on anti-HCV, anti-HBc
nd HIV seroprevalence and the factors associated
ith these infections among Egyptian prisoners.
The HCV-Ab prevalence in this study was 15.8%,
hich is higher than that detected in the general
opulation (14.7%) [13].
Several studies have observed higher HCV preva-
ences in imprisoned populations. A study in a
razilian female prison found an HCV seropreva-
ence of 16.2% [14]. An HCV seroprevalence range
p
t
cctor.
f 16—41% was identiﬁed in an incarcerated popu-
ation in the USA, and approximately 12—35% of the
risoners had chronic hepatitis C [15].
Our study reports a signiﬁcant difference in
CV seroprevalence with respect to gender, with
higher prevalence in males. Ford et al. reported
hat the seroprevalence was 39.8% among the
emale inmates [16], while other studies did not dif-
erentiate between male and female inmates [17].
It has been reported that HCV RNA can be
etected in 40—90% of subjects that are positive for
CV antibodies [13]. In our population, 61 (77.2%)
f the inmates positive for HCV antibodies tested
ositive for HCV RNA. This information corrobo-
ates the hypothesis that prisoners are important
arriers of HCV and are a potential source of trans-
ission.
Future studies will have to investigate whether
etecting HCV viremia for all incoming prisoners
ia routine HCV RNA testing will be useful. These
tudies should weigh the beneﬁts of the potential
revention of HCV transmission and the possible
herapeutic consequences against the signiﬁcant
osts of such a testing regimen [18].
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Approximately 10% of our prisoners had evidence
of antibodies against the hepatitis B core antigen.
The results of this study are in agreement with ear-
lier studies by Schreiber et al., which reported that
Egypt has an intermediate prevalence (2—8%) of
HBV infection [19]. Our reported prevalence is also
similar to those reported in Irish (8.7%) and United
Kingdom (8%) prisons [20,21].
In contrast, the prevalence of HIV in our prison
populations was zero. This may be an accurate
reﬂection of the very low prevalence of HIV in
the Egyptian population, with an estimated adult
prevalence rate of less than 0.01% [22].
Coexisting HCV and HBV infections have been
estimated at 1.2% in our study. However, dual infec-
tions with HBV and HCV were detected in 10%
of the Egyptian general population, while isolated
anti-HBc, a marker of previous HBV exposure, was
reported in 45% of chronic hepatitis C patients. This
high ﬁgure for anti-HBc suggests a common route of
transmission for both viruses [23].
This study indicates that a history of intravenous
drug use is the most important risk factor for
both HBV and HCV infections. This result agrees
with previous studies. Although both infections
are prevalent among this risk group population,
the impact of HCV infection is profound, and
urgent intervention is required to curb drug abuse
[24—26]. Weild et al. reported that the prevalence
of anti-HCV among adult IDUs was 31%, while the
prevalence of anti-HBc was 20%. Therefore, it is less
likely, but not impossible, that this virus is transmit-
ted in prison [21].
In certain countries, successful educational pro-
grams have been developed to reduce the risk
of hepatitis and HIV transmission among IDUs.
In England and Wales, measures to reduce the
spread of blood-borne virus infections in prisons
include health promotion, vaccination against hep-
atitis B, a range of options for coming off drugs
and methadone treatment for opiate withdrawal.
The distribution of bleach tablets to disinfect
injecting equipment was piloted in 1998. Bleach
is an intervention for when IDUs have no safer
alternative. The once-only use of sterile needles
and syringes is considered to be the most effec-
tive preventive measure. The absence of needle
exchanges within prisons puts IDU prisoners at a
disadvantage compared to IDUs in the community
[21].
We identiﬁed an effect of tattooing on HCV
seroprevalence. However, HBV infection was not
signiﬁcantly associated with tattooing. Tattooing
is common in prison populations and, as reported
elsewhere, seems to be associated with HBV and
HCV infections. This is an important ﬁnding because
o
i
a
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here is poor general awareness of the risk of tat-
ooing in Egypt. Studies that speciﬁed the venue
f tattooing showed no deﬁnitive evidence for an
ncreased risk of HCV infection when tattoos and
iercings were received in professional parlors.
owever, the risk of HCV infection is signiﬁcantly
ncreased by tattooing, particularly among high-risk
roups that receive tattoos in prison settings or by
riends [27].
It has been suggested that previous imprison-
ent is associated with HCV infection [28]. In
ur study, we reported a signiﬁcant association by
nivariate analysis of previous imprisonment with
ositive HCV serology, but not HBV. A higher pro-
ortion of subjects with previous imprisonment
ere IDUs, likely explaining the higher HCV sero-
revalence. This variable was also identiﬁed as
n independent risk factor for HCV infection by
uimarães et al. [28].
The participants who spent more time in prison
ver the previous 10 years and those who shared
oiletries while in prison were signiﬁcantly more
ikely to be positive for antibodies to HCV and HBV.
revious studies reported that individuals incarcer-
ted for a longer time were 2.44 times more likely
o be HCV-positive [29]. There was also clear evi-
ence that equipment is frequently shared among
nmates, and the risk of equipment contamination
y parenterally transmitted viruses is higher within
he prison system than outside of it. Measures to
inimize the spread of hepatitis within prisons are
ssential. In addition, prison is an appropriate time
or interventions by educating prisoners about the
isks of hepatitis transmission and providing vacci-
ations [30].
Our study reported that having a dental pro-
edure was a signiﬁcant independent risk factor
or HCV infection. Lock et al. demonstrated that
considerable proportion of toothbrushes used by
epatitis C patients were contaminated with HCV
NA [31]. Egyptian patients with periodontal dis-
ase exhibited higher rates of anti-HCV and/or
nti-HBc antibodies than the controls [32].
Other proposed routes of transmission do not
eem to be relevant in the studied population. All
f the subjects denied a history of sharing nee-
les and homosexuality. Some studies have stated
hat homosexuality leads to a greater chance of
CV infection. This association was not conﬁrmed
n our study [33,34]. All of the subjects positive for
CV antibodies denied homosexual practices. This
nding suggests that the association identiﬁed in
ther studies might be related to other risk behav-
ors rather than homosexuality itself, which is in
ccordance with Fox et al. [35] and Mahfoud et al.
36].
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tepatitis C, hepatitis B and HIV infection among Eg
Due to religious beliefs, abnormal sexual
elationships are not common in the Egyptian com-
unity. Therefore, we suspected that we might
eceive non-truthful answers to this question. Nev-
rtheless, all of the prisoners denied abnormal
exual behavior.
Being over 45 years of age was associated with
ositive serology for HCV, a ﬁnding that was also
bserved in other studies [37—39]. This may be
xplained by a higher risk of exposure to HCV over
ime.
DM was strongly associated with HC and HBV
nfections. The association of HCV and DM is com-
lex, and some studies suggest that the higher
revalence of DM is a result of more severe liver
isease in HCV- and HBV-infected groups [40]. Other
tudies have shown that a higher prevalence of DM
n HCV-infected patients is attributable to a higher
revalence of DM in African Americans with HCV
41].
The clinical course of liver disease was rather
ild in our study. Approximately 15.8% of the pris-
ners were anti-HCV positive, and 77.2% had HCV
iremia. This was compared to only 9.8% having
nti-HBc antibodies, and the predominant poten-
ial cause of chronic liver diseases (CLD) was HCV
nfection. When the morbidity data were analyzed
ccording to HCV and HBV infection status, DM
as detected in 19.7% of HCV-infected individuals
ompared with 4.1% with HBV infection alone. How-
ver, other signiﬁcant differences were observed
etween patients with HBV and HCV infections,
uch as elevated ALT levels, cirrhosis, high BMI and
hrombocytopenia.
Strickland et al. reported that anti-HCV-positive
ase patients were more likely to have elevated
LT levels and ultrasound ﬁndings of cirrho-
is. Consistent with previous reports, anti-HBc
tatus was not statistically associated with cirrho-
is, ALT, AST, albumin levels or platelet counts
42].
In a case—control study by Andrew and col-
ogues to determine the seroprevalence of HCV
nfection in a cohort of 594 diabetics, DM was
bserved in 21% of HCV-infected patients compared
ith 12% of HBV-infected subjects. Because there
ere signiﬁcant differences between the HCV and
BV cohorts, no ﬁrm conclusions could be drawn
rom this analysis concerning the relative con-
ribution of each variable to glucose intolerance
43].
One of the important hematological ﬁndings
n our study was thrombocytopenia, as 48.1%
f HCV-positive prisoners had thrombocytopenia.
hrombocytopenia is not only important for HCV
s a mere association but also because it has been
p
v
m
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roposed as a signiﬁcant predictive indicator of
sophageal varices in HCV patients [44].
It was recommended that patients with lone
hrombocytopenia should be screened for HCV, par-
icularly in endemic areas or where blood and blood
roducts are not properly screened [45].
We observed that obesity was signiﬁcantly more
ommon among HCV-positive patients than hepati-
is B-positive patients. This was in agreement with
hen et al., who reported that obesity may be more
revalent in people who test positive for HCV anti-
odies than in the general population. The presence
f HCV viremia may be associated with an increased
isk of obesity [46].
HCV infection was more signiﬁcantly associated
ith cirrhosis than HBV infection. The predomi-
ant potential cause of chronic liver disease was
nfection with HCV. Several other reports that
onﬁrmed low rates of cirrhosis in HCV patients
ighlighted the slow speed of disease progression
47]. Thus, large-scale interferon-based therapies
or young men in prison may be needed to pre-
ent severe liver disease. Additionally, successful
ntiviral therapy could prevent further HCV trans-
ission.
The frequency of cirrhosis in this study was sim-
lar to other previously reported patient groups
10,42]. However, our results might underestimate
he frequency of cirrhosis, as diagnoses based on
clinical discriminate score are less sensitive than
istopathologic diagnoses.
Now is the time for policy makers, researchers
nd clinicians working in prisons to ensure that
rison does not unnecessarily add to the health risks
f this already disadvantaged population.
Limitations to this study must be considered.
irst, as only a single prison was included, the data
re not representative of the entire Egyptian prison
ystem, and a selection bias may have occurred.
owever, this bias was minimized by the broad
eographic diversity of the selected prisoners. Sec-
ndly, the statuses of IDUs were determined by
elf-reporting, and prisoners may be reluctant to
dmit a history of use due to fear of possible con-
equences, such as additional punishment. Finally,
he questionnaire did not address socioeconomic
actors, such as income and education, which gen-
rally are good indicators of low awareness of viral
isease transmission.
Despite these limitations, we can still conclude
hat there is a strong need for HCV care (i.e.,
esting and treatment) in prisons. The high intra-
rison prevalence of HBV underscores the need to
accinate prison populations. Initiation of control
easures to prevent continued transmission after
ncarceration should be undertaken.
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